Oncology Consultants’ Post

Succeeding with Innovation: The State of Radioligand Therapy Readiness in Europe - IQVIA As an effective and traditional nuclear medicine for cancer care Radioligand therapy (RLT) is emerging as an essential pillar in cancer care. It is a targeted treatment approach that has shown clinical benefits in treating gastroenteropancreatic neuroendocrine tumors and advanced prostate cancer. It is also being researched as a promising treatment modality for several other advanced cancers. The scientific innovation in radioligand therapies is progressing rapidly, however, the healthcare system readiness for this treatment modality is lagging. There is a critical and urgent need to enhance the understanding of the current level of readiness for RLT across countries and to address issues impacting this in order to ensure patient access in a timely and equitable manner. https://lnkd.in/e2WbA_GQ

Excited to share our latest findings on bimodal radiation therapy for sinonasal malignancies! 📚 Our recent phase-II study, demonstrated promising results with low rates of acute toxicity. 🩺 Key Numbers: 👥 35 patients treated (76% T4) ⚡️ combined IMRT (50 Gy) and carbon ion boost (24 Gy(RBE)) 💉 Acute mucositis grade III in only 12% (n=4) 🚫 No high-grade (≥grade III) long-term side effects 👉2-year-OS 79.4%, 2-year-PFS 61.8%, 2-year-MFS 64.8% Our study demonstrates the first prospective data on bimodal radiation therapy for sinonasal malignancies. 🌟 for details - open access: https://lnkd.in/eEPzyF6t #Oncology #RadiationTherapy #MedicalResearch 📊👩⚕️🔬 Marburg Ion-Beam Therapy Centre MIT Radiation Oncology Marburg Universitätsklinikum Heidelberg (UKHD) National Center for Tumor Diseases (NCT) Heidelberg

📜 Najnovije vesti! U okviru projekta TargetedResponse objavljen je novi rad pod nazivom ,,Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors". Ceo rad možete pronaći i pročitati na linku: https://lnkd.in/d9d_QY86 We're thrilled to announce the publication of our latest research paper titled "Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors" by Project TargetedResponse. Check out the full paper and join us in advancing cancer research: https://lnkd.in/d9d_QY86 #fondzanauku #IDEJE #TargetedResponse #programideje #science #nauka #CancerResearch #LungCancer #NSCLC #PersonalizedMedicine #TKI #ScientificResearch

In this recent publication, researchers at Emory University’s Department of Hematology and Medical Oncology and the Winship Cancer Institute of Emory University describe the development and assessment of a class of bisbiguanides (AX-4 and AX-7, analogs of alexidine) as disrupters of mitochondria and cell invasion, adding them to the list of promising compounds aimed at limiting cancer metastasis. Utilizing transmission electron microscopy (TEM) methods and making use of our Georgia Research Alliance-funded Hitachi HT7700 (Hitachi Electron Microscope) and our JEOL JEM 1400 (JEOL USA) TEMs at the Robert P. Apkarian Integrated Electron Microscopy Core (www.cores.emory.edu/iemc), the authors examined the effects of analog treatment on mitochondria ultrastructure. Find the article here: https://lnkd.in/e7Mvz-fV #EmoryUniversity #IEMC #EICF #GRA #EmorySOM #Winship #CancerResearch #CancerMetastasis #ResearchBreakthrough #TEM #ultrastructure #bisbiguanides #NIH #NCI #GeorgiaResearchAlliance

ARA is on the leading edge with PSMA radiopharmaceutical treatment for advanced metastatic prostate cancer! How does it work? 1) Treatment is infused through an IV. 2) The radiopharmaceutical seeks out prostate cells (in black) anywhere they have metastasized in the body. 3) The radiopharmaceutical attaches to the prostate cancer cells and delivers a microscopic amount of radiation. 4) The radiation kills the cancer cells, leaving surrounding healthy tissue (in white) unharmed. Find out more on the new ARA Theranostics website at https://lnkd.in/g5nfCTgq #prostatecancer #prostate #theranostics #theragnostics #radiology #nuclearmedicine #health #cancer #medical #technology #medicalimaging #menshealth #araimaging #araproud #austinhealth #austintx #austin #atx #austintexas #texas #atxlocal #austincommunity #austinpost #healthcare

A Comparative Study: Proton Beam Therapy Vs Traditional Radiation for Prostate Cancer This research provides a thorough comparison between Intensity-Modulated Proton Therapy (IMPT) and Intensity-Modulated Radiation Therapy (IMRT) for the management of high-risk prostate cancer. This study meticulously examines the differential impact of these therapies on side effects that significantly affect patient quality of life. Key Highlights: ●Reduced Toxicities: IMPT significantly lowers gastrointestinal and genitourinary side effects compared to IMRT. ●Enhanced Patient Outcomes: IMPT improves the overall treatment experience, promoting quicker recoveries and less disruption to patients’ lives. ●Clinical Relevance: Supports broader use of IMPT in treating high-risk prostate cancer due to its superior safety and efficacy. ●Future Implications: Encourages further research into the long-term benefits and potential of IMPT in oncological care. Click here to read full article: https://lnkd.in/dphCyrcM Chilukuri Srinivas Sham Sundar Dayananda shamurailatpam #APCC #WinningOverCancer #ProtonTherapy #healthcare

🌈 "Beyond #binary: bridging #neutrophil #diversity to new therapeutic approaches in #NSCLC" 🌈 Our in-depth review exploring the diversity and functionality of tumor-associated neutrophils (#TAN) in non-small cell lung cancer (#NSCLC) is now published! We highlight how TAN subclusters are not static; they adapt dynamically to the tumor microenvironment's (#TME) cues, including hypoxia and signals from #cancer cells. This plasticity underscores the potential for innovative therapeutic strategies that precisely target specific TAN subclusters, opening new avenues for anticancer interventions! #ICB #IO #teamwork https://lnkd.in/dHJEnzhm

ANZUP Cancer Trials Group Limited present #TheraP follow-up in The Lancet Lutetium-177 PSMA-617 is an alternative to cabazitaxel chemotherapy - less toxicity and no difference in survival. PET represents a novel prognostic biomarker.   https://lnkd.in/gsB4bYyP Lot's of new data in this follow-up paper including PET Imaging as a Novel Prognostic Biomarker, both PSMA and FDG. Outcomes of patients we who were excluded owing to low PSMA uptake or FDG-positive discordant patient. For the scientists: check out the Supplementary Appendix as well! Thanks to Prostate Cancer Foundation of Australia | ANSTO | Movember | NHMRC Clinical Trials Centre | Novartis | Prostate Cancer Foundation (supporting my time) Maybe the best example of a trial with nuclear medicine & medical oncology (🙏Ian Davis) collaborating seamlessly? Thanks to everyone involved, patients and their carers, nurses, clinical trial staff, radio-pharmaceutical scientists

𝐑𝐚𝐝𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲: 𝐀 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐨𝐚𝐝𝐦𝐚𝐩 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 (RA/QM opportunity aswell!) Cancer is a leading cause of death worldwide, and its incidence is only expected to increase in the coming years. Radiotherapy is a vital tool in the fight against cancer, but access to this treatment is still very limited in many parts of the world. A white paper from the International Atomic Energy Agency (IAEA) provides a roadmap for the future of radiotherapy, with a focus on improving access and quality of care for all patients. The paper highlights a number of key areas for action, including: 1. Expanding access to radiotherapy 2. Improving the quality of radiotherapy 3. Promoting research and innovation The IAEA white paper is a timely and important contribution to the global effort to improve cancer care. It provides a clear roadmap for the future of radiotherapy, and it calls on all stakeholders to work together to make this a reality. 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐲𝐨𝐮 𝐠𝐞𝐭 𝐢𝐧𝐯𝐨𝐥𝐯𝐞𝐝? Luckily Consult has partnered with the market leader for radiotherapy and dosimetry in their search to bring RAs and QMs on board. If you want to get involved with the wellbeing of cancer patients and build a career out of it, now is your chance. 𝘈𝘱𝘱𝘭𝘺 𝘩𝘦𝘳𝘦: https://lnkd.in/eUXfs-w7 #regulatory #QMS #hiring #radiotherapy #innovation #dosimetry

📃Scientific paper: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities Abstract: International audience; Abstract In this chapter, we address the role of radiation as treatment modality in the context of oncological treatments given to patients. Physical aspects of the use of ionizing radiation (IR)—by either photons, neutrons, or charged (high linear energy transfer) particles—and their clinical application are summarized. Information is also provided regarding the radiobiological rationale of the use of conventional fractionation as well as alternative fractionation schedules using deviating total dose, fraction size, number of fractions, and the overall treatment time. Pro- and contra arguments of hypofractionation are discussed. In particular, the biological rationale and clinical application of Stereotactic Body Radiation Therapy (SBRT) are described. Furthermore, background information is given about FLASH radiotherapy (RT), which is an emerging new radiation method using ultra-high dose rate allowing the healthy, normal tissues and organs to be spared while maintaining the antitumor effect. Spatial fractionation of radiation in tumor therapy, another method that reduces damage to normal tissue is presented. Normal tissue doses could also be minimized by interstitial or intraluminal irradiation, i.e., brachytherapy, and herein an overview is given on the principles of brachytherapy and its clinical application. Furthermore, details are provided regarding the principles, clinical application, and limitations of boron neutron c... Continued on ES/IODE ➡️ https://etcse.fr/KYEtT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.